NKMAX, Alzheimer's Phase 1 Clinical Trial Progressing Smoothly..."Patient Enrollment Underway"

[Asia Economy Reporter Hyunseok Yoo] NKMax announced on the 5th that it has completed the registration of 3 out of 21 Alzheimer's patients participating in Phase 1 clinical trials and is currently conducting PET-CT scans before administering the SuperNK autologous immune cell therapy (SNK01). The company plans to perform the first patient blood collection in the first week of December and the first patient injection (First Injection) in mid-December.

Phase 1 clinical trials received IND approval in August and have also obtained the Material Transfer License for the import and export customs clearance of cell therapy products in Mexico to proceed with the clinical trial. This trial targets 21 patients with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD).

▲ The trial divides 9 patients into three groups to administer SNK01 doses of 1 billion, 2 billion, and 4 billion cells respectively, four times each, to determine the Maximum Tolerated Dose (MTD). Subsequently, ▲ the safety, tolerability, and exploratory efficacy of SNK01 at the MTD will be evaluated in 12 patients.

Paul Y. Song, Vice President of NKMax America, stated, “This clinical trial, led by Professor Ming Guo of UCLA School of Medicine, a leading expert in Alzheimer's research in the United States, is being conducted at Hospital Angeles Tijuana, the largest hospital in Mexico, following the recommendations of the U.S. FDA. Although the Alzheimer's market is predicted to reach $12.6 billion, there are no prescribed treatments available. This will be the only treatment for the Alzheimer's market, which has more than 5 million patients in the U.S. alone.”

This content was produced with the assistance of AI translation services.